This is a binary catalyst event for a micro-cap biotech — positive Phase IIb data could drive significant upside, while negative or inconclusive data would likely be value-destructive. Monitor for enrollment updates and topline data readouts. The cross-filing context (20-F annual report) provides no new financial guidance or material changes.
Price Chart
Executive Summary
SciSparc's subsidiary NeuroThera Labs announced the initiation of a Phase IIb clinical trial site at Yale Child Study Center for SCI-110, a cannabinoid-based drug candidate for Tourette Syndrome. The trial builds on a Phase IIa study that showed a 21% average tic reduction. This is a clinical milestone for a pre-revenue micro-cap biotech, but no financial data, guidance, or regulatory filing was provided — the event is a routine pipeline update with binary long-term outcomes.
Key Facts
- NeuroThera Labs launched a Phase IIb clinical trial site at Yale Child Study Center for SCI-110, a cannabinoid-based treatment for Tourette Syndrome.
- The Phase IIb trial is a randomized, double-blind, placebo-controlled, cross-over study in adults aged 18-65.
- The primary efficacy endpoint is change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26.
- Phase IIa data showed an average tic reduction of 21% across the entire participant sample.
- The trial is also underway at Hannover Medical School (Germany) and Tel Aviv Sourasky Medical Center (Israel).
- SciSparc has a market cap of approximately $4M and is a pre-revenue clinical-stage pharmaceutical company.
Financial Impact
No financial data provided in the filing. SciSparc is a pre-revenue clinical-stage company with a $4M market cap.
Risk Factors
- Phase IIb trial may fail to meet primary or secondary endpoints.
- SciSparc has a very small market cap ($4M) and limited cash runway — future dilution risk is high.
- Regulatory approval for SCI-110 is years away and uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-085420 |
| Document: ea030069702ex99-1.htm | 0001213900-26-085420 |
| Document: 0001213900-26-085420-index-headers.html | 0001213900-26-085420 |
| Document: 0001213900-26-085420-index.html | 0001213900-26-085420 |
| Document: 0001213900-26-085420.txt | 0001213900-26-085420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers